Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Cancer is major disease occurring every year and 6 million new patients are diagnosed and more than 4 million die. This represents 10% of all death and half of those who are diagnosed as having cancer and two-thirds of those who die of cancer are in developing countries. Around 55% of the patients undergoing treatment for cancer experience pain. Cancer pain has most common cause in patients by tumor spread, metastatic bone disease, nerve compression and hollow-viscus and retroperitoneal involvement. The second pain involved in the cancer pain is associated with cancer therapy. Cancer pain can be improved with better cancer diagnosis and treatment and by understanding of analgesic drug therapy. In addition surge in prevalence of cancer and increase in adoption of cancer pain drugs for treatment is expected to fuel the demand for cancer pain market
The global cancer pain market is anticipated to have growth at the highest rate during the forecast period. The key factor driving the growth of cancer pain market is increasing healthcare expenditures for the treatment of cancer patients providing advanced treatment and facilities. Beside increase in government initiatives to alleviate cancer is further fueling the demand for cancer pain market. Also rise in public awareness and advance cancer pain therapeutics is providing opportunity to the key player to introduce innovative drug in market. Surge in geriatric population is playing pivotal role the growth of cancer pain market
The exclusive COVID 19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the cancer pain market. In addition, complete analysis of changes on the cancer pain market expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on global economies, international trade, business investments, GDP and marketing strategies of key players present in the market. COVID-19 impact on the cancer pain market was moderate due to safety concern session of different treatment were arranged accordingly maintain the norms and rule of COVID-19 which fuel the demand for cancer pain market to some extend
The cancer pain market is segmented based on by disease type, by treatment, by drug type, by end user and geography
The cancer pain are majorly found in different disease types including lung cancer, colorectal cancer, breast cancer, prostate cancer, blood cancer
Lung cancer is expected to dominate in the global cancer pain market due to increasing case of cancer in both men and women due to geriatric population, surge in cigarette smoking population. The lung cancer is majorly observed and diagnose in older people i.e. 65 or older. Thereby there is a high surge in the use of cancer painkillers to get relief from pain which is majorly driving the growth of cancer pain market.
The cancer pain have various treatment available in market like immunotherapy, radiotherapy, chemotherapy
Chemotherapy is a drug treatment that uses powerful chemicals to kill fast-growing cells in cancer, as cancer cells grow and multiply much faster than most cells in the body. Besides immunotherapy is a type of biological therapy which helps the immune system to fight against cancer.
The cancer pain has different drug type available in market like opioids, non-opioids, nerve blockers
Opioids are widely used for the treatment of mild to moderate cancer pain. These opioids are necessary for cancer patients as these provide natural substances (called endorphins) made by the body to control pain. The growth of segment is due to increasing adoption of opioids in the management of cancer pain, and rise in prevalence of severe cancer pain.
The cancer pain market has its major end use in hospitals, homecare, specialty clinics
Hospital is expected to have significant growth in global cancer pain market attributing to increasing patient inflow of type cancer types. As the hospital seek to provide specialty services such as medical, surgery& radiation oncology, palliative care, pain management and supportive services which is ultimately fueling the growth of cancer pain market
Geographically the global cancer pain market is studied for the following region North America, Europe, Asia-Pacific and Rest of the world (RoW)
North America is estimated to lead in the cancer pain market accounting significant share due to advanced healthcare infrastructure and healthcare spending. In addition, increasing number of cancer diseases patient in the region is further fueling the demand for cancer pain market in the region. Whereas Europe is second largest growing regional attributing to developed healthcare infrastructure and high diagnosis rate with precise result. On the other hand Asia Pacific is anticipated to witness the growth at highest rate due to large population and growing awareness of cancer treatment among people, and increased government spending on providing enhanced healthcare services to the people is further driving the regional growth. Countries like China, Brazil, and India are expected to have high growth due increasing investments by the government to enhance the healthcare facilities.
The key players in cancer pain market are Aoxing Pharmaceutical Company, Inc., BioDelivery Sciences International, Inc., Daiichi Sankyo Co., Ltd., Grunenthal Pharma GmbH & Co. KG, Hisamitsu Pharmaceutical Co., Inc., Insys Therapeutics, Inc., Mundipharma International Limited, Eli-Lilly, Orexo AB, Pfizer Inc., Sanofi, Meda Pharmaceuticals, Johnson & Johnson, Teva Pharmaceutical Industries Limited, Galena Biopharma, GW Pharmaceuticals, Hospira, ProStrakan Group and Sorrento Therapeutics among others.
The report analyses the global cancer pain market based on disease type, treatment, drug type, end user and geography. The cancer pain are majorly found in different disease types including lung cancer, colorectal cancer, breast cancer, prostate cancer, blood cancer. The cancer pain have various treatment available in market like immunotherapy, radiotherapy, chemotherapy. The cancer pain has different drug type available in market like opioids, non-opioids, nerve blockers. The cancer pain market has its major end use in hospitals, homecare, specialty clinics. Geographically the global cancer pain market is studied for the following region North America, Europe, Asia-Pacific and Rest of the world (RoW)
The key players in cancer pain market are Aoxing Pharmaceutical Company, Inc., BioDelivery Sciences International, Inc., Daiichi Sankyo Co., Ltd., Grunenthal Pharma GmbH & Co. KG, Hisamitsu Pharmaceutical Co., Inc., Insys Therapeutics, Inc., Mundipharma International Limited, Eli-Lilly, Orexo AB, Pfizer Inc., Sanofi, Meda Pharmaceuticals, Johnson & Johnson, Teva Pharmaceutical Industries Limited, Galena Biopharma, GW Pharmaceuticals, Hospira, ProStrakan Group and Sorrento Therapeutics among others.
Why to buy this report:
